CDDO-Im

• CAT Number: I003570
• CAS Number: 443104-02-7
• Molecular Formula: C34H43N3O3
• Molecular Weight: 541.72
• Purity: ≥95%
• Target: PPARγ agonist
• Solubility: 10 mM in DMSO
• Storage: 2-8°C
• IUPAC Name: (4aR,6aR,6aS,6bR,8aS,12aS,14bS)-8a-(imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile
• InChI: InChI=1S/C34H43N3O3/c1-29(2)10-12-34(28(40)37-15-14-36-20-37)13-11-33(7)26(22(34)18-29)23(38)16-25-31(5)17-21(19-35)27(39)30(3,4)24(31)8-9-32(25,33)6/h14-17,20,22,24,26H,8-13,18H2,1-7H3/t22-,24-,26-,31-,32+,33+,34-/m0/s1
• InChIKey: ITFBYYCNYVFPKD-FMIDTUQUSA-N
• SMILES: CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)N6C=CN=C6)C

CDDO-Im (Cat No.:I003570) is a compound that activates nuclear factor erythroid2–related factor2 (Nrf2) and peroxisome proliferator-activated receptor (PPAR). It binds to PPARα and PPARγ with Ki values of 232nM and 344nM, respectively. CDDO-Im exhibits inhibitory effects on inflammatory responses and tumor growth in vivo. Its ability to modulate Nrf2 and PPAR pathways makes it a potential candidate for therapeutic interventions targeting inflammation and cancer.

Reference

[1]. Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.
[2]. Hughes DT, et al. The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. Cancer Invest. 2008 Mar;26(2):118-27.
[3]. Reisman SA, et al. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):109-14.
[4]. So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616.